October 1, 1998Journal of Cardiovascular Electrophysiology
Cisapride‐Induced Torsades de Pointes
Population
2 patients with torsades de pointes associated with cisapride and concomitant drug therapy inhibiting its…
Design
Case_series
Authors
Discussion
Loading...
Member takes
Implication
May warrant avoiding cisapride with CYP inhibitors; leaves open confirmation of interaction predictability in larger cohorts.
Key Points
- To describe the mechanism and clinical circumstances underlying torsades de pointes associated with cisapride administration.
- Clinical evaluation of two cases presenting with torsades de pointes during cisapride therapy alongside concurrent metabolic inhibitor medications.
- Measurement of plasma cisapride concentration days following the arrhythmogenic event in one patient.
- Both patients developed torsades de pointes during co-administration of cisapride and drugs known to inhibit its biotransformation.
- Plasma cisapride remained markedly elevated days after the arrhythmia in one evaluated patient, demonstrating that drug accumulation rather than an idiosyncratic reaction mediated cardiac toxicity.
Structured PICO
P
Population
2 patients with torsades de pointes associated with cisapride and concomitant drug therapy inhibiting its biotransformation
I
Intervention
Cisapride with concomitant drug therapy that inhibits cisapride biotransformation
O
Outcome
Torsades de pointessafety
Cisapride-induced torsades de pointes is a predictable adverse reaction caused by drug accumulation when co-administered with inhibitors of its biotransformation.
Cite This Study
Vítola et al. (1998) studied this question.